All patients must have a histologically or cytologically diagnosis of prostate cancer and must be eligible for radical prostatectomy.
Eastern Cooperative Oncology Group (ECOG) Performance Status score ≤1.
All patients must complete mpMRI or 68Ga-PSMA PET / CT before and after neoadjuvant treatment.
All patients must undergo thorough tumor staging and meet one of the following criteria: 1. multi-parameter MRI or PSMA PET / CT shows clinical staging of primary tumor ≥ cT2c or cN+or locally advanced, 2. Gleason score of primary tumor ≥ 8, 3. prostate specific antigen (PSA) ≥20 ng/ml.
Patients must have adequate organ function as defined by the following criteria(within 28 days prior to registration):
white blood cell (WBC) ≥ 4.0 × 109 / L platelets≥ 100 × 109 / L hemoglobin ≥ 9 g / dL international normalized ratio (INR) \< 1.5. total bilirubin (TBIL)≤1.5 x upper limit of normal (ULN) SGOT (AST) and SGPT (ALT) ≤ 2.5 x ULN serum creatinine ≤2×ULN
Patients must participate voluntarily and sign an informed consent form (ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must be willing to obey the prohibitions and restrictions specified in the research protocol.
You may not be if
clinical or radiological evidence of regional or extra-regional lymph node metastases or bone metastases or visceral metastases.
Prior androgen deprivation therapy (medical or surgical) or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy.
severe or uncontrolled concurrent infections.
New York Heart Association Class III or IV congestive heart failure at the time of screening.
uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection.
Patients have had other malignancies other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled.
Clareo Health | Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
